Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIDING trial of sivelestat adjunct to remifentanil in mechanically ventilated ICU patients
ChiCTR2400086632Phase 2Not yet recruiting
- Sponsor
- Affiliated Huai'an Hospital of Xuzhou Medical University
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sivelestat and remifentanil in critical illness (2 arms), sponsored by Affiliated Huai'an Hospital of Xuzhou Medical University. Primary endpoint: Average remifentanil consumption per kilogram body weight per hour during 96 hours after randomization. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
sivelestatremifentanil
03
Conditions
critical illness
Beyond the preview
Go deeper on ChiCTR2400086632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086632.